$STRO
SUTRO BIOPHARMA, INC.

2020 Q2 Form 10-Q Financial Statement

#000156459020036997 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $9.469M $10.53M
YoY Change -10.03% 84.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.640M $8.070M
YoY Change 7.06% 99.75%
% of Gross Profit
Research & Development $17.24M $16.14M
YoY Change 6.81% 17.4%
% of Gross Profit
Depreciation & Amortization $1.060M $1.190M
YoY Change -10.92% 5.31%
% of Gross Profit
Operating Expenses $17.24M $24.21M
YoY Change -28.78% 36.07%
Operating Profit -$13.69M
YoY Change 13.21%
Interest Expense $46.29M -$110.0K
YoY Change -42181.82% -69.44%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $29.87M -$13.79M
YoY Change -316.61% 19.5%
Income Tax
% Of Pretax Income
Net Earnings $29.87M -$13.79M
YoY Change -316.57% 19.51%
Net Earnings / Revenue 315.47% -131.05%
Basic Earnings Per Share $1.00 -$0.60
Diluted Earnings Per Share $0.94 -$0.60
COMMON SHARES
Basic Shares Outstanding 29.90M 22.93M
Diluted Shares Outstanding 31.78M 22.93M

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $250.5M $153.2M
YoY Change 63.51% 503.15%
Cash & Equivalents $65.35M $19.39M
Short-Term Investments $185.1M $133.8M
Other Short-Term Assets $2.900M $2.600M
YoY Change 11.54% 62.5%
Inventory
Prepaid Expenses
Receivables $5.100M $6.500M
Other Receivables $0.00 $0.00
Total Short-Term Assets $258.5M $162.2M
YoY Change 59.35% 437.16%
LONG-TERM ASSETS
Property, Plant & Equipment $11.30M $9.273M
YoY Change 21.86% -22.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.600M $15.10M
YoY Change -62.91%
Other Assets $2.100M $2.239M
YoY Change -6.21% -27.77%
Total Long-Term Assets $19.00M $26.59M
YoY Change -28.54% 77.26%
TOTAL ASSETS
Total Short-Term Assets $258.5M $162.2M
Total Long-Term Assets $19.00M $26.59M
Total Assets $277.5M $188.8M
YoY Change 46.97% 317.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.900M $4.516M
YoY Change 8.5% 67.26%
Accrued Expenses $4.500M $3.565M
YoY Change 26.23% -13.05%
Deferred Revenue $21.38M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $5.800M
YoY Change -100.0% 190.0%
Total Short-Term Liabilities $35.50M $36.10M
YoY Change -1.66% 88.02%
LONG-TERM LIABILITIES
Long-Term Debt $24.30M $7.000M
YoY Change 247.14% -48.53%
Other Long-Term Liabilities $11.00M $125.0K
YoY Change 8700.0% -98.56%
Total Long-Term Liabilities $35.30M $7.125M
YoY Change 395.44% -68.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.50M $36.10M
Total Long-Term Liabilities $35.30M $7.125M
Total Liabilities $70.80M $69.26M
YoY Change 2.23% 66.88%
SHAREHOLDERS EQUITY
Retained Earnings -$185.5M -$168.0M
YoY Change 10.39%
Common Stock $287.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $206.8M $119.6M
YoY Change
Total Liabilities & Shareholders Equity $277.5M $188.8M
YoY Change 46.97% 317.73%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $29.87M -$13.79M
YoY Change -316.57% 19.51%
Depreciation, Depletion And Amortization $1.060M $1.190M
YoY Change -10.92% 5.31%
Cash From Operating Activities -$12.50M -$15.60M
YoY Change -19.87% 11.83%
INVESTING ACTIVITIES
Capital Expenditures -$1.770M -$490.0K
YoY Change 261.22% 1125.0%
Acquisitions
YoY Change
Other Investing Activities -$55.37M $9.680M
YoY Change -672.0%
Cash From Investing Activities -$57.14M $9.190M
YoY Change -721.76% -23075.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 91.42M -820.0K
YoY Change -11248.78% -102.5%
NET CHANGE
Cash From Operating Activities -12.50M -15.60M
Cash From Investing Activities -57.14M 9.190M
Cash From Financing Activities 91.42M -820.0K
Net Change In Cash 21.78M -7.230M
YoY Change -401.24% -138.5%
FREE CASH FLOW
Cash From Operating Activities -$12.50M -$15.60M
Capital Expenditures -$1.770M -$490.0K
Free Cash Flow -$10.73M -$15.11M
YoY Change -28.99% 8.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7315
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7289
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8396
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7489
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0185
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0162
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0255
CY2019Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
1050000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23098969
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23098969
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8876000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
409000
CY2019Q4 us-gaap Debt Current
DebtCurrent
1000000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4406000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6017000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
19465000
CY2020Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
49094000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
128568000
CY2019Q4 us-gaap Assets
Assets
156370000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
16195000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9633000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5584000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2545000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
901000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32967000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
15609000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6298000
CY2019Q4 us-gaap Liabilities
Liabilities
58581000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
134000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
97789000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156370000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17243000
CY2020Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
384000
CY2019Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1124000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10525000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1025000
us-gaap Operating Expenses
OperatingExpenses
52218000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35597000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16621000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13685000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195745000
CY2020Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2813000
CY2019Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
5497000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
29872000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
370000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30242000
CY2019Q2 stro Interest And Other Expense Net
InterestAndOtherExpenseNet
1232000
us-gaap Net Income Loss
NetIncomeLoss
10277000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13793000
us-gaap Net Income Loss
NetIncomeLoss
-28043000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
stro Interest And Other Expense Net
InterestAndOtherExpenseNet
2392000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
293346000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
165000
CY2020Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
48860000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
48860000
stro Interest And Other Expense Net
InterestAndOtherExpenseNet
4011000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
29872000
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
CY2020Q2 stro Interest And Other Expense Net
InterestAndOtherExpenseNet
2955000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
131539000
us-gaap Operating Expenses
OperatingExpenses
47105000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19154000
CY2019Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2329000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
10413000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15782000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27951000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2300000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13793000
us-gaap Net Income Loss
NetIncomeLoss
10277000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
233000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
260000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13636000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
10510000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27783000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
97789000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
646000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2707000
CY2020Q1 stro Warrants Issued During Period Value In Connection With Debt Refinancing
WarrantsIssuedDuringPeriodValueInConnectionWithDebtRefinancing
619000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-137000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19595000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
82085000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3011000
CY2020Q2 stro Common Stock Issuance Costs
CommonStockIssuanceCosts
6626000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
91411000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
370000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
29872000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
206757000
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
10327000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
671000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2286000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
103000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14250000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
130718000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2463000
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
157000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13793000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
119555000
us-gaap Profit Loss
ProfitLoss
10277000
us-gaap Profit Loss
ProfitLoss
-28043000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2158000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-54000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1263000
us-gaap Share Based Compensation
ShareBasedCompensation
5718000
us-gaap Share Based Compensation
ShareBasedCompensation
4749000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
48860000
stro Remeasurement Of Liability Awards
RemeasurementOfLiabilityAwards
-1979000
stro Remeasurement Of Liability Awards
RemeasurementOfLiabilityAwards
-28000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-322000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-208000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1196000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4011000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1497000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2652000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-413000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
103000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
79000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
20000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8889000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1475000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-406000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1969000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1309000
stro Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
63800000
stro Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
14500000
stro Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
7000000
stro Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
2529000
stro Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
765000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15499000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68885000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
91411000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
25000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
10000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
646000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
671000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
107121000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1277000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60388000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-105908000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4975000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125313000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65363000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19405000
us-gaap Interest Paid Net
InterestPaidNet
649000
us-gaap Interest Paid Net
InterestPaidNet
633000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1286000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
146000
stro Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
1128000
stro Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
1717000
stro Warrants Issued To Lenders
WarrantsIssuedToLenders
619000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Principal Activities</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sutro Biopharma, Inc. (the “Company”), is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders. The Company was incorporated on April 21, 2003 and is headquartered in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, the development of biopharmaceutical products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">May 2020 Public Offering</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.33%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 14, 2020, the Company closed a public offering of 12,650,000 shares of its common stock at a public offering price of $7.75 per share, which included the exercise in full of the underwriters’ option to purchase 1,650,000 shares of common stock. <span style="Background-color:#FFFFFF;color:#000000;">The gross proceeds from this offering were approximately $98.0 million, before deducting approximately $6.6 million of underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $91.4M to the Company.  </span> </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Vaxcyte Equity Ownership</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, Vaxcyte, formerly known as SutroVax, Inc, closed its initial public offering (“IPO”) of its common stock at a price per share of $16.00. As of June 30, 2020, the Company held 1,634,005 shares of Vaxcyte common stock, which are subject to a lock-up agreement that expires in December 2020.  </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Vaxcyte common stock held by the Company will be measured at fair value at each reporting period based on the closing price of Vaxcyte’s common stock on the last trading day of each reporting period, adjusted for a discount for lack of marketability (DLOM) due to the lock-up agreement, with any unrealized gains and losses recorded in the Company’s statements of operations. As of June 30, 2020, the estimated fair value of the Vaxcyte common stock held by the Company was $49.1 million. The Company recognized an unrealized gain related to Vaxcyte common stock of $48.9 million for the three and six months ended June 30, 2020, of which $49.1 million was from the estimated fair value of Vaxcyte common stock, offset by a $0.2 million adjustment related to a revaluation of a prior preferred stock warrant converted to common stock.  See Note 2—“Investment in Equity Securities,” Note 3—“Fair Value Disclosures,” Note 4 — “Cash and Marketable Securities”, and Note 7—“Related Party Transactions”.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and has negative cash flows from operations. As of June 30, 2020, the Company had an accumulated deficit of $185.5 million. Management expects to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities and costs to operate as a public company. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the Company had unrestricted cash, cash equivalents and marketable securities of $207.0 million, which are available to fund future operations. The Company believes that its unrestricted cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient for the Company to continue for at least one year from the issuance date of its unaudited interim condensed financial statements.    </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will need to raise additional capital to support the completion of its research and development activities and its operations.</p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2003-04-21
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185500000
CY2020Q2 stro Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue
207000000.0
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
204493000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
402000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
204891000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
131499000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
168000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
131664000
CY2020Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
5600000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
15600000
CY2020Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
25000000.0
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
4500000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65348000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19390000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15000
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65363000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19405000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
23500000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2020Q2 stro Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
100000
CY2019Q4 stro Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
100000
CY2020Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
200000
CY2019Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
400000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1000000.0
CY2020Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0807
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0808
CY2020Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
200000
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
300000
us-gaap Interest Expense Debt
InterestExpenseDebt
600000
CY2019Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0887
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0888
CY2019Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
85000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
175000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8691304
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7357234
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
81000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
55000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.97
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3011000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2463000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5718000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4749000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
191165
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
191165
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
66685
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
8890
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
75475
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
266740
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
266640
CY2020Q2 stro Liability Attributable To Call Option Plan
LiabilityAttributableToCallOptionPlan
2100000
CY2019Q4 stro Liability Attributable To Call Option Plan
LiabilityAttributableToCallOptionPlan
76000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
29872000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13793000
us-gaap Net Income Loss
NetIncomeLoss
10277000
us-gaap Net Income Loss
NetIncomeLoss
-28043000
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29900913
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22926390
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26510873
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22895902
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31777960
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22926390
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28538279
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22895902
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.94
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4433656

Files In Submission

Name View Source Status
0001564590-20-036997-index-headers.html Edgar Link pending
0001564590-20-036997-index.html Edgar Link pending
0001564590-20-036997.txt Edgar Link pending
0001564590-20-036997-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stro-10q_20200630.htm Edgar Link pending
stro-10q_20200630_htm.xml Edgar Link completed
stro-20200630.xsd Edgar Link pending
stro-20200630_cal.xml Edgar Link unprocessable
stro-20200630_def.xml Edgar Link unprocessable
stro-20200630_lab.xml Edgar Link unprocessable
stro-20200630_pre.xml Edgar Link unprocessable
stro-ex311_8.htm Edgar Link pending
stro-ex312_9.htm Edgar Link pending
stro-ex321_7.htm Edgar Link pending
stro-ex322_6.htm Edgar Link pending